Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib as add-on therapy in mild Alzheimer's disease
NCT05564169Phase 3Not yet recruiting
- Sponsor
- AB Science
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of masitinib in Alzheimer's disease (AD), sponsored by AB Science. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
masitinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05564169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564169.